Erasca, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

20 Mar 2025

ERAS

10-K: Erasca Reports Full Year 2024 Results, Prioritizes Key Programs

Erasca, a clinical-stage oncology company, announces its full year 2024 results, highlighting progress in its RAS/MAPK pathway-focused pipeline and a strategic reprioritization of resources.

NASDAQ

27 Mar 2024

ERAS

Erasca, INC

10-K: Erasca's 2023 10-K Filing: Focus on RAS/MAPK Pathway Therapies

Erasca's 2023 10-K filing highlights its focus on developing therapies for RAS/MAPK pathway-driven cancers, with three clinical-stage programs and a deep pipeline.